Immunome

Targeted-oncology biotech building a multi-modality pipeline anchored by varegacestat, an oral once-daily gamma secretase inhibitor for desmoid tumors with a Phase 3 win and 2Q 2026 NDA submission planned. Early-stage portfolio leverages a proprietary HC74 TOP1i payload across ROR1 and first-in-class solid-tumor ADCs plus an FAP radioligand therapy entering Phase 1.